SDAI plans to develop and commercialize longevity-focused biotech portfolio
- SDAI established a five-member scientific board chaired by Professor Brian Kennedy to guide its transformation into a longevity-focused biotechnology company.
- The board will guide research priorities, evaluate emerging science for commercialization and strengthen research partnerships.
- The group plans to develop longevity products and services tailored to Asian consumers, targeting new revenue opportunities.
- The transformation aims to establish a sustainable business model that would support an application to resume trading in due course.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SDAI Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: G4Y7CDQ52IXDJKOC) on November 04, 2026, and is solely responsible for the information contained therein.